<DOC>
	<DOCNO>NCT01158846</DOCNO>
	<brief_summary>In set ST elevation myocardial infarction newer therapy recently study , follow encouraging result , introduce clinical practice . Prasugrel show valid alternative overcome limitation clopidogrel therefore provide well ischemic protection . On hand , bivalirudin least beneficial heparin/abciximab anticoagulant agent associate few hemorrhagic event . The primary hypothesis study combination prasugrel plus bivalirudin associate well risk/benefit profile .</brief_summary>
	<brief_title>Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel Patients Presenting With STEMI</brief_title>
	<detailed_description>Background : In set STEMI , adjunctive pharmacological therapy play key role acute management . Along clear benefit mechanical reperfusion strategy , several drug show beneficial . On top clopidogrel , heparins IIB/IIIa glycoprotein , drug recently introduce show encouraging result . These `` new '' drug , namely prasugrel bivalirudin , compare separately . Primary hypothesis : combination prasugrel/bivalirudin superior combination clopidogrel heparin/abciximab term net adverse clinical event , i.e . ischemic event plus hemorrhagic event Setting : - patient present ST-elevation myocardial infarction undergo primary PCI Mechanical reperfusion : -primary percutaneous coronary intervention Pharmacological Interventions : - Two arm : Clopidogrel plus heparin/abciximab v Prasugrel plus Bivalirudin Follow : - 1 year Measurements : - efficacy end point term reduction ischemic event - safety end point term reduction bleeding event</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>ST elevation myocardial infarction No contraindication primary PCI Known intolerance/allergy one study drug component Clinical indication treatment oral anticoagulant , include use warfarin dabigatran oral anticoagulant agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>STEMI</keyword>
	<keyword>Primary PCI</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>antiplatelets</keyword>
</DOC>